The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876
Open accessAbstract
The recent progresses in understanding of cancer glycolytic phenotype have offered new strategies to manage ovarian cancer and other malignancies. However, therapeutic targeting of glycolysis to treat cancer remains unsuccessful due to complex mechanisms of tumor glycolysis and the lack of selective, potent and safe glycolytic inhibitors. Recently, BAY-876 was identified as a new-generation inhibitor of glucose transporter 1 (GLUT1), a GLUT isoform commonly overexpressed but functionally poorly defined in ovarian cancer. Notably, BAY-876 has not been evaluated in any cell or preclinical animal models since its discovery. We herein took advantage of BAY-876 and molecular approaches to study GLUT1 regulation, targetability, and functional relevance to cancer glycolysis. The anti-tumor activity of BAY-876 was evaluated with ovarian cancer cell line- and patient-derived xenograft (PDX) models. Our results show that inhibition of GLUT1 is sufficient to block basal and stress-regulated glycolysis, and anchorage-dependent and independent growth of ovarian cancer cells. BAY-876 dramatically inhibits tumorigenicity of both cell line-derived xenografts and PDXs. These studies provide direct evidence that GLUT1 is causally linked to the glycolytic phenotype in ovarian cancer. BAY-876 is a potent blocker of GLUT1 activity, glycolytic metabolism and ovarian cancer growth, holding promise as a novel glycolysis-targeted anti-cancer agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BAY-876, a potent GLUT1 inhibitor49, was separately shown as an effective candidate in pre-clinical setting 50.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Sundaram, S. K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T. R., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,719
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., Deck, L. M., Royer, R. E., Jagt, D. L. V., Semenza, G. L., & Dang, C. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914433107 · Cited by 1,528
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484
The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes
Levine, A. J., & Puzio-Kuter, A. M. (2010) · Science · doi:10.1126/science.1193494 · Cited by 1,243
The hypoxic tumour microenvironment
Petrova, V., Annicchiarico‐Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,077
Glucose transporters in the 21st Century
Thorens, B., & Mueckler, M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00712.2009 · Cited by 1,013
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells
Yun, J., Rago, C., Cheong, I., Pagliarini, R., Angenendt, P., Rajagopalan, H., Schmidt, K., Willson, J. K. V., Markowitz, S., Zhou, S., et al. (2009) · Science · doi:10.1126/science.1174229 · Cited by 914
Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc
Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D. R., Lee, L. A., & Dang, C. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000023200 · Cited by 876
Regulation of glut1 mRNA by Hypoxia-inducible Factor-1
Chen, C., Pore, N., Behrooz, A., Ismail‐Beigi, F., & Maity, A. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010144200 · Cited by 769
Metabolic Modulation of Glioblastoma with Dichloroacetate
Michelakis, E. D., Sutendra, G., Dromparis, P., Webster, L., Haromy, A., Niven, E. B., Maguire, C., Gammer, T.-L., Mackey, J. R., Fulton, D. S., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000677 · Cited by 744
Liu, Y., Cao, Y., Zhang, W., Bergmeier, S. C., Qian, Y., Akbar, H., Colvin, R. A., Ding, J., Tong, L., Wu, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0131 · Cited by 586
Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality
Chan, D. A., Sutphin, P. D., Nguyen, P., Turcotte, S., Lai, E. W., Banh, A., Reynolds, G. E., Chi, J., Wu, J. J., Solow-Cordero, D. E., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002394 · Cited by 563
Glucose transporters in cancer – from tumor cells to the tumor microenvironment
Ancey, P., Contat, C., & Meylan, E. (2018) · FEBS Journal · doi:10.1111/febs.14577 · Cited by 531
Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake
Flavahan, W. A., Wu, Q., Hitomi, M., Rahim, N., Kim, Y., Sloan, A. E., Weil, R. J., Nakano, I., Sarkaria, J. N., Stringer, B. W., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3510 · Cited by 511
Glucose transporters: physiological and pathological roles
Navale, A. M., & Paranjape, A. N. (2016) · Biophysical Reviews · doi:10.1007/s12551-015-0186-2 · Cited by 495
The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function
Scheepers, A., Joost, H., & Schurmann, A. (2004) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607104028005364 · Cited by 476 · cited 1×
“There are two classes of glucose transporters, sodium-dependent glucose transporter (SGLT) and facilitative glucose transporter (GLUT) [12].”
BackgroundMaschek, G., Savaraj, N., Priebe, W., Braunschweiger, P. G., Hamilton, K., Tidmarsh, G. F., Young, L. R. D., & Lampidis, T. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3294 · Cited by 452
Tumour-associated mutant p53 drives the Warburg effect
Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434
Chen, J., & Russo, J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.06.004 · Cited by 340
Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876
Siebeneicher, H., Cleve, A., Rehwinkel, H., Neuhaus, R., Heisler, I., Müller, T., Bauser, M., & Buchmann, B. (2016) · ChemMedChem · doi:10.1002/cmdc.201600276 · Cited by 294
Hendrix, N. D., WU, R. T., Kuick, R. D., Schwartz, D. R., Fearon, E. R., & Cho, K. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3694 · Cited by 278
GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker
Carvalho, K. C., da Cunha, I. W., Rocha, R. M., Ayala, F. R. R., Cajaiba, M. M., Begnami, M. D., VILELA, R. S., Paiva, G. R., Andrade, R. G., & Soares, F. A. (2011) · Clinics · doi:10.1590/s1807-59322011000600008 · Cited by 230
Yao, C.-H., Liu, G., Wang, R., Moon, S. H., Gross, R. W., & Patti, G. J. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2003782 · Cited by 222
Kapoor, K., Finer-Moore, J. S., Pedersen, B. P., Caboni, L., Waight, A. B., Hillig, R. C., Bringmann, P., Heisler, I., Müller, T. M., Siebeneicher, H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603735113 · Cited by 221
Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors
Samanta, D., & Semenza, G. L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.002 · Cited by 190
Xintaropoulou, C., Ward, C., Wise, A., Marston, H. M., Turnbull, A., & Langdon, S. P. (2015) · Oncotarget · doi:10.18632/oncotarget.4499 · Cited by 161
Mondal, S., Roy, D., Bhattacharya, S. S., Jin, L., Jung, D., Zhang, S., Kalogera, E., Staub, J. K., Wang, Y., Xuyang, W., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31868 · Cited by 154
Shao, H., Mohamed, E., Xu, G. G., Waters, M. R., Jing, K., Ma, Y., Zhang, Y., Spiegel, S., Idowu, M. O., & Fang, X. (2015) · Oncotarget · doi:10.18632/oncotarget.6757 · Cited by 137
Self-citationGuest editorial: The conception of FDG-PET imaging
Alavi, A. A., & Reivich, M. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.29269 · Cited by 120
Ojelabi, O., Lloyd, K. P., Simon, A. H., Zutter, J. K. D., & Carruthers, A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.759175 · Cited by 108
Xintaropoulou, C., Ward, C., Wise, A., Queckbörner, S., Turnbull, A., Michie, C. O., Williams, A. R. W., Rye, T., Gourley, C., & Langdon, S. P. (2018) · BMC Cancer · doi:10.1186/s12885-018-4521-4 · Cited by 107
SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma
Kim, Y. H., Jeong, D. C., Pak, K., Han, M., Kim, J., Liu, L., Kim, H. J., Kim, T. W., Kim, T. H., Hyun, D. W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20266 · Cited by 105
Phadngam, S., Castiglioni, A., Ferraresi, A., Morani, F., Follo, C., & Isidoro, C. (2016) · Oncotarget · doi:10.18632/oncotarget.13113 · Cited by 86
Quercetin inhibits glucose transport by binding to an exofacial site on GLUT1
Hamilton, K. E., Rekman, J. F., Gunnink, L. K., Busscher, B. M., Scott, J. L., Tidball, A. M., Stehouwer, N. R., Johnecheck, G. N., Looyenga, B. D., & Louters, L. L. (2018) · Biochimie · doi:10.1016/j.biochi.2018.05.012 · Cited by 84
Avanzato, D., Pupo, E., Ducano, N., Isella, C., Bertalot, G., Luise, C., Pece, S., Bruna, A., Rueda, O. M., Caldas, C., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3018 · Cited by 82
NAMPT Is the Cellular Target of STF-31-Like Small-Molecule Probes
Adams, D., Ito, D., Rees, M. G., Seashore-Ludlow, B. A., Puyang, X., Ramos, A. H., Cheah, J. H., Clemons, P. A., Warmuth, M., Zhu, P., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb500347p · Cited by 81
Martin, H.-J., Kornmann, F., & Fuhrmann, G. F. (2003) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2003.06.001 · Cited by 80
Investigational cancer drugs targeting cell metabolism in clinical development
Sborov, D. W., Haverkos, B. M., & Harris, P. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.960077 · Cited by 72
Mukherjee, A., Ma, Y., Yuan, F., Gong, Y., Fang, Z., Mohamed, E., Berrios, E., Shao, H., & Fang, X. (2015) · Neoplasia · doi:10.1016/j.neo.2015.09.003 · Cited by 56
Self-citationSalas, M., Obando, P., Ojeda, L., Ojeda, P. G., Pérez, A., Vargas‐Uribe, M., Rivas, C. I., Vera, J. C., & Reyes, A. M. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00387.2012 · Cited by 52
Identification of novel GLUT inhibitors
Siebeneicher, H., Bauser, M., Buchmann, B., Heisler, I., Müller, T. H., Neuhaus, R., Rehwinkel, H., Telser, J., & Zorn, L. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.050 · Cited by 49
Fibulin-3 promotes muscle-invasive bladder cancer
Han, A., Veeneman, B. A., El-Sawy, L., Day, K. C., Day, M. L., Tomlins, S. A., & Keller, E. T. (2017) · Oncogene · doi:10.1038/onc.2017.149 · Cited by 46
Ma, Y., Yu, C., Mohamed, E., Shao, H., Wang, L., Sundaresan, G., Zweit, J., Idowu, M. O., & Fang, X. (2016) · Oncogene · doi:10.1038/onc.2016.150 · Cited by 45
Self-citationToxicity and clinical tolerance of lonidamine.
della Cuna, G. R., & Pedrazzoli, P. (1991) · PubMed · Cited by 40
Salicylketoximes That Target Glucose Transporter 1 Restrict Energy Supply to Lung Cancer Cells
Granchi, C., Qian, Y., Lee, H. Y., Paterni, I., Pasero, C., Iegre, J., Carlson, K. E., Tuccinardi, T., Chen, X., Katzenellenbogen, J. A., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201500320 · Cited by 24
Ma, Y., Min, H., Oh, U., Hawkridge, A. M., Wang, W., Mohsin, A. A., Chen, Q., Sanyal, A. J., Lesnefsky, E. J., & Fang, X. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.812925 · Cited by 15
Self-citationKopitz, C., Toschi, L., Algire, C., Héroult, M., Frisk, A.-L., Meyer, K., Schmitz, A., Lagkadinou, E., Petrul, H. M., Heisler, I., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4746 · Cited by 9
Flagged first, then by citations
Research works printed but not linked: 1
- Warburg, 1924, üeber den Stoffwechsel der Tumoren, Biochem. Z., 152, 319
Cited by
Sorted by citations
Metabolomics in cancer research and emerging applications in clinical oncology
Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Heiden, M. G. V., & Locasale, J. W. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21670 · Cited by 675
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Wu, Q., Ba-Alawi, W., Deblois, G., Cruickshank, J., Duan, S., Lima‐Fernandes, E., Haight, J., Tonekaboni, S. A. M., Fortier, A.-M., Kuasne, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18020-8 · Cited by 305
TGFβ-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer
Hua, W., ten Dijke, P., Kostidis, S., Giera, M. A., & Hornsveld, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03398-6 · Cited by 245
Gao, T., Zhang, X., Zhao, J., Zhou, F., Wang, Y., Zhao, Z., Xing, J., Chen, B., Li, J., & Liu, S. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.029 · Cited by 158
Metadata
- Authors
- Ma, Y., Wang, W., Idowu, M. O., Oh, U., Wang, X.-Y., Temkin, S. M., & Fang, X.
- Affiliations
- Virginia Commonwealth University (US)
- Corresponding author
- Fang, Xianjun
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-12-31
- Volume
- 11
- Issue
- 1
- Pages
- 33
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6356953
- OpenAlex
- W2907710771
- Cited by
- 145
- References
- 51
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 21 · 2023: 25 · 2022: 18 · 2021: 27 · 2020: 9 · 2019: 14
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (P30 CA16059)
- Astar Biotechnology Research award (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- ovarian cancer, glucose transporter 1, GLUT1, BAY-876, glycolysis, cancer metabolism, glycolysis inhibitors, tumor growth, patient-derived xenografts, anchorage-independent growth, anticancer activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
